Patient Engagement Best Practices
Intricacies of Cross-Border M&A
In this webinar you will learn what COVID-19 means for today’s cross-border deals, current deal landscape, pre-deal considerations, effects on negotiation of pricing and valuation, deal execution logistics, considerations for deal professionals working remotely, managing corporate and tax issues, and tools to streamline transactions, reduce risks, and increase efficiency.
What's Hot and What's Not in Oncology Licensing in 2020?
M&A and Capital Raising for Medical Groups, Life Sciences and Healthcare Companies
This webinar gives medical groups, life sciences, and healthcare companies in the lower middle market an understanding of financing and M&A alternatives available, the role of financial buyers, key issues around selling equity in your business, and the typical financing and M&A process.
Adoptive Cell Therapy in Solid Tumors
Predictable Failure (And How to Avoid It) for Early-Stage Life Science Companies
In this webinar, Dr. Lucia Mokres breaks down the six major stakeholder categories relevant to most life science companies, and shares key strategies for closing the knowledge gap between founders and their market success.
Quality By Design: Remote Monitoring and eTMF Integration
Pullan’s Pieces Part III – A Business Development View of the Immunology Landscape
Must-Know Finance Concepts for Life Sciences Valuations - Part II
This webinar discusses which asset valuation methodology is most used by big pharma to evaluate possible partners or acquisitions and an explanation of three fundamental concepts in valuation: risk-adjusted value, cost of capital, and present value.
Essential Steps to Successful BioPharma Partnering
What's Hot & What's Not in Antibody Drug Conjugates Licensing
In this webinar, learn what targets are suitable, what are the trends in linkers and the drugs to be attached to the antibodies, how are companies dealing with the complexities of internalization and high cost of goods, what kind of data will drive an ADC licensing deal, how do the ADCs fit in the world of immuno-oncology and what is the future for ADCs.